New hope for PAH patients: Extended-Release tacrolimus enters phase 3 trial
Disease control
Not yet recruiting
This Phase 3 study tests VI-0106, an extended-release form of tacrolimus, in 300 people with pulmonary arterial hypertension (PAH) who still have trouble with daily activities despite taking standard PAH medications. Participants will receive either the drug or a placebo for 24 w…
Phase: PHASE3 • Sponsor: VIVUS LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC